DDT-BMQ-00086 End-Stage Knee Osteoarthritis as a Prognostic Biomarker for Knee Osteoarthritis Trials

DDT-BMQ-00086 末期膝骨关节炎作为膝骨关节炎试验的预后生物标志物

基本信息

  • 批准号:
    10410084
  • 负责人:
  • 金额:
    $ 24.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The FDA recognizes osteoarthritis as a serious disease since it is a leading cause of pain, disability, and arthroplasty with few effective treatments and none accepted to reduce its overall progression. Barriers to developing effective therapies include failure to enrich study samples with people likely to progress and an absence of structural endpoints that “reliably predict reduced pain, increased function, or prolonged time to end-stage disease”. Specifically, we lack a structural endpoint or proxy indicator of severe knee osteoarthritis. Receipt of a knee replacement is often used as a patient-centered endpoint for knee osteoarthritis, but this has a highly variable relationship with biological measures of knee osteoarthritis severity and a strong dependence on extraneous influences (e.g., expectations, mental and physical readiness for surgery). These aspects render knee replacements unreliable as a consistent disease severity endpoint. Also, the low frequency of knee replacement as an outcome requires sample sizes infeasible for most clinical trials. To overcome these barriers, we introduced a composite definition reflecting “end-stage knee osteoarthritis” (esKOA), which combines patient-reported outcomes with structural severity measures to eliminate the influence of extraneous factors in designating this disease status. Our consensus panel of experts adapted this definition from an appropriateness algorithm for knee arthroplasty that was further developed and validated for epidemiologic studies. In brief, esKOA is present in a knee with 1) severe radiographic osteoarthritis (Kellgren- Lawrence [KL] grade = 4 out of 4) with moderate-intense pain or 2) KL grade < 4 with intense or severe pain and limited mobility or instability. The FDA Center for Drug Evaluation and Research accepted our application to enroll esKOA into their Biomarker Qualification Program with a proposed context of use as a “prognostic biomarker panel for use in clinical trials with subjects with a diagnosis of knee osteoarthritis to identify patients who are likely to experience long-term disease progression…requiring knee replacement surgery”. To address the critical next steps, we will use knee-based analyses of data from the Osteoarthritis Initiative (8,888 knees from 4,479 people), which is a longitudinal multicenter observational cohort explicitly designed to develop knee osteoarthritis biomarkers. Specifically, we will aim to determine how each component of esKOA and their proposed thresholds “relate to disease progression towards esKOA [Aim 1] and how they [and esKOA] may contribute to identification of patients who progress or will not progress to knee replacement [Aim 2]”. Furthermore, we will assess whether a “composite made of both biomarker and clinical outcome assessment components may be unnecessarily complicated” and could be simplified. This proposal will further the development of esKOA as a prognostic biomarker for future knee replacement. This prognostic biomarker will be made publicly available to enrich a study sample for clinical trials or in early-phase trials to demonstrate an intervention’s therapeutic potential.
FDA认为骨关节炎是一种严重的疾病,因为它是导致关节炎的主要原因。 疼痛、残疾和关节成形术,几乎没有有效的治疗方法,也没有人接受减少其整体 进展开发有效疗法的障碍包括未能丰富研究样本, 进展和缺乏结构性终点,"可靠地预测疼痛减轻,功能增加,或 终末期疾病的时间延长"。具体来说,我们缺乏一个严重的结构性终点或代理指标, 膝关节骨性关节炎。接受膝关节置换术通常被用作膝关节置换术的以患者为中心的终点。 骨关节炎,但这与膝关节骨关节炎严重程度的生物学指标之间存在高度可变的关系 以及对外来影响的强烈依赖(例如,期望,心理和身体准备, 外科手术)。这些方面使得膝关节置换术作为一致的疾病严重度终点不可靠。还有, 膝关节置换的低频率作为结果需要的样本量对于大多数临床试验来说是不可行的。 为了克服这些障碍,我们引入了一个反映“终末期膝关节骨关节炎”的复合定义 (esKOA),将患者报告的结局与结构严重程度指标相结合,以消除 在指定这种疾病状态的外来因素的影响。我们的专家共识小组改编了这个 膝关节置换术适当性算法的定义,该算法进一步开发和确认, 流行病学研究。简而言之,esKOA存在于1)严重放射学骨关节炎(Kellgren- Lawrence [KL]等级= 4/4)中度-剧烈疼痛或2)KL等级<4伴有剧烈或重度疼痛 以及有限的移动性或不稳定性。FDA药物评估和研究中心接受了我们的申请 将esKOA纳入其生物标志物资格认证计划,并建议将其用作"预后 用于诊断为膝骨关节炎的受试者的临床试验中以识别患者的生物标志物组 可能经历长期疾病进展.需要膝关节置换手术"。解决 接下来的关键步骤,我们将使用基于膝关节的数据分析,这些数据来自骨关节炎倡议(8,888个膝关节 来自4,479人),这是一项纵向多中心观察性队列研究,明确设计用于膝关节 骨关节炎生物标志物。具体来说,我们将致力于确定esKOA的每个组成部分及其 提出的阈值"与疾病向esKOA的进展有关[目标1],以及它们[和esKOA]如何 有助于识别进展或不会进展至膝关节置换术的患者[目标2]"。 此外,我们将评估“由生物标志物和临床结果评估组成的复合物”是否 组件可能不必要地复杂",并且可以简化。这一建议将进一步推动 开发esKOA作为未来膝关节置换术的预后生物标志物。这种预后生物标志物将 公开提供,以丰富临床试验或早期试验的研究样本,以证明 干预的治疗潜力。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeffrey B Driban其他文献

Jeffrey B Driban的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeffrey B Driban', 18)}}的其他基金

Environmental Factors Associated with the Development of Osteoarthritis
与骨关节炎发展相关的环境因素
  • 批准号:
    10558833
  • 财政年份:
    2023
  • 资助金额:
    $ 24.78万
  • 项目类别:
Interpretation and Utility of Novel Composite Structural Endpoints of Cumulative Damage and Disease Activity in Knee Osteoarthritis
膝骨关节炎累积损伤和疾病活动的新型复合结构终点的解释和应用
  • 批准号:
    10408670
  • 财政年份:
    2021
  • 资助金额:
    $ 24.78万
  • 项目类别:
Interpretation and Utility of Novel Composite Structural Endpoints of Cumulative Damage and Disease Activity in Knee Osteoarthritis
膝骨关节炎累积损伤和疾病活动的新型复合结构终点的解释和应用
  • 批准号:
    10633223
  • 财政年份:
    2021
  • 资助金额:
    $ 24.78万
  • 项目类别:
Characterization of Rapidly Progressive Knee Osteoarthritis
快速进展性膝骨关节炎的特征
  • 批准号:
    9029298
  • 财政年份:
    2015
  • 资助金额:
    $ 24.78万
  • 项目类别:

相似海外基金

DDT-BMQ-000109, Qualification of biomarkers for in vitro developmental toxicity screening in a human system
DDT-BMQ-000109,人体系统体外发育毒性筛选生物标志物的资格
  • 批准号:
    10836889
  • 财政年份:
    2023
  • 资助金额:
    $ 24.78万
  • 项目类别:
DDT-BMQ-0000100 Qualification of the Plasmodium falciparum 18S rRNA biomarker for malaria-endemic controlled human malaria infection studies
DDT-BMQ-0000100 疟疾流行控制人类疟疾感染研究中恶性疟原虫 18S rRNA 生物标志物的鉴定
  • 批准号:
    10836140
  • 财政年份:
    2023
  • 资助金额:
    $ 24.78万
  • 项目类别:
TGx-DDI (DDT-BMQ-000008) ring trial: a cross-site validation study of an in vitro transcriptomic biomarker for genotoxicity testing
TGx-DDI (DDT-BMQ-000008) 环试验:用于遗传毒性测试的体外转录组生物标志物的跨站点验证研究
  • 批准号:
    10409881
  • 财政年份:
    2022
  • 资助金额:
    $ 24.78万
  • 项目类别:
DDT-BMQ-0000107 Qualification of the Plasmodium falciparum 18S rRNA biomarker for malaria field studies
DDT-BMQ-0000107 用于疟疾现场研究的恶性疟原虫 18S rRNA 生物标志物的鉴定
  • 批准号:
    10616035
  • 财政年份:
    2022
  • 资助金额:
    $ 24.78万
  • 项目类别:
DDT-BMQ-000079 Establishing Performance Characteristics of the Epidermal Neurite Density (END) Biomarker to Assist Diagnosis of Small Fiber Neuropathy
DDT-BMQ-000079 建立表皮神经突密度 (END) 生物标志物的性能特征以辅助诊断小纤维神经病
  • 批准号:
    10619324
  • 财政年份:
    2022
  • 资助金额:
    $ 24.78万
  • 项目类别:
Sample Collection and Analysis to Support the Qualification Plan for Drug Induced Skeletal Muscle Injury Biomarker Panel for DDT-BMQ-000081.
样品采集和分析以支持 DDT-BMQ-000081 药物引起的骨骼肌损伤生物标志物小组的资格计划。
  • 批准号:
    10411471
  • 财政年份:
    2021
  • 资助金额:
    $ 24.78万
  • 项目类别:
Sample Collection and Analysis to Expand Demographics Diversity of Reference Range for the Final Qualification Package for GLDH Activity as a Biomarker of Drug Induced Liver Injury (DDT-BMQ-000050)
样品采集和分析,以扩大 GLDH 活性作为药物性肝损伤生物标志物的最终资格包参考范围的人口统计多样性 (DDT-BMQ-000050)
  • 批准号:
    10411701
  • 财政年份:
    2021
  • 资助金额:
    $ 24.78万
  • 项目类别:
Systematic Analysis and Threshold Synthesis for |G*| as a Diagnostic Biomarker for NAFLD and NASH Clinical Trials - DDT-BMQ-000099
|G*| 的系统分析和阈值合成
  • 批准号:
    10410011
  • 财政年份:
    2021
  • 资助金额:
    $ 24.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了